Objective: The current predictive models based on main clinical tumor features are not accurate for the biggest bladder cancer patient group, who underwent the transurethral resection (TUR). Method: Overall 103 patients with primary urocarcinoma after TUR were included in this retrospective study. The follow up plan in all cases included cystoscopy and biopsy every 3 months in the first 2 years. The recurrence criteria were cystoscopical and pathological confirmation of the tumor growth. In all cases using TMA technique (TMA Master, 3DHistech) there was done the IHC expression study of p53, p63, CK20, E-cadherine, B-catenin, CD44v6, Ki-67 (10 % cut-off), Topo-II-a (10 % cut-off) and Her2, as well c-erb-B2 amplification study (CISH). Results: There were no association found between the Her2 expression and c-erb-B2 amplification in urocarcinoma patients. In multivariate regression analysis only CK20, Ki-67 and Topo-II-a showed the significant prognostic power in recurrence prediction. These markers were used to develop the powerful predictive index for bladder cancer patients after TUR. Conclusion: Although the Her2 overexpression is relatively common event in bladder cancer, c-erb-B2 gene amplification isn't main mechanism of its realization. The CK20, Ki-67 and Topo-II-a are promising prognostic markers for recurrence and should be validated in further prospective study.